Obesity rates in America by year: what the data shows

Obesity rates in America by year: what the data shows

This analysis summarizes obesity rates in America by year using the strongest available public-health data and explains why the trend matters for pharma BD and investors. It also places U.S. prevalence in the context of global obesity statistics and the standard BMI definition.

IntelligenceRegulatory Impact▾

FDA and EMA decisions frame this story. Regulatory relevance is medium for obesity. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• In 2024, all U.S. states and territories had an obesity prevalence of 25% or higher, meaning at least 1 in 4 adults in every jurisdiction meets the clinical threshold.
• Worldwide adult obesity has more than doubled since 1990, with 890 million adults living with obesity in 2022.
• A BMI of 30 or higher remains the standard classification for obesity in adults, a metric that has defined the condition for decades.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low for obesity. Expect implications for pricing, access, and launch sequencing.

What the data shows: obesity rates in America by year

The most current CDC data show that in 2024, every U.S. state and territory had an obesity prevalence of 25% or higher. This uniform floor across all jurisdictions reflects the geographic breadth of obesity in America. While regional variation exists—some areas report substantially higher rates—no U.S. state or territory falls below the 25% threshold.

According to Harvard's Nutrition Source, which cites CDC data, 1 in 3 adults in the U.S. has obesity. The consistency of these prevalence estimates across surveillance systems indicates obesity remains a high-prevalence condition in America. The U.S. obesity and overweight rate reflects both the breadth and depth of the condition across demographic groups and geographic regions.

IntelligenceStrategic Takeaways▾

In 2024, all U.S. states and territories had an obesity prevalence of 25% or higher , meaning at least 1 in 4 adults in every jurisdiction meets the clinical threshold. Worldwide adult obesity has more than doubled since 1990 , with 890 million adults living with obesity in 2022. A BMI of 30 or higher remains the standard classification for obesity in adults , a metric that has defined the condition for decades.

Global obesity statistics: scale and momentum

The U.S. obesity prevalence sits within a much larger global context. Worldwide adult obesity has more than doubled since 1990. In absolute terms, 890 million adults were living with obesity in 2022, according to WHO data. This scale—roughly 1 in 8 people globally—indicates that obesity statistics worldwide now extend across multiple regions and income levels. The global prevalence growth establishes a substantial population base affected by the condition.

IntelligenceEvidence Quality▾

Grounded in 2 regulatory sources.

BMI: the standard measurement for obesity in adults

A BMI of 30 or higher has been the standard classification for obesity in adults for decades. This metric—derived from height and weight—serves as the primary screening tool in clinical and epidemiological settings. BMI remains the convention used across public health surveillance and clinical practice for defining and measuring obesity in adults.

What this means for pharma BD and clinical strategy

The uniform elevation of obesity prevalence across all U.S. states and territories at 25% or higher, combined with the scale of global obesity, establishes a substantial and distributed population affected by the condition. For pharma BD teams and investors, these data points indicate sustained clinical need across multiple geographies. The fact that every U.S. jurisdiction reports obesity prevalence at or above 25% demonstrates the breadth of the addressable population for obesity-related programs and interventions.

The global obesity trend—890 million adults affected worldwide—reinforces that obesity represents a multinational population base for clinical development and commercial activity. The consistent use of BMI 30+ as a diagnostic standard across public health systems also provides a standardized epidemiological framework for trial design and population assessment. For BD teams evaluating obesity-related development opportunities, the combination of universal U.S. prevalence elevation and sustained global growth suggests ongoing demand for prevention and treatment programs across regions.

Frequently Asked Questions

Related coverage

• MariTide Phase 2 obesity data show up to 20% weight loss at one year
• Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
• Manufacturing pipeline approvals: what the evidence confirms